PLEASANTON, CA - Shareholders of 10x Genomics (NASDAQ:TXG), Inc., a laboratory analytical instruments company, participated in a virtual annual meeting on June 11, 2024, to vote on several key proposals, as disclosed in a recent SEC filing.
With a 93.10% turnout of the eligible votes, shareholders elected Kimberly J. Popovits as a Class II director for a term expiring at the company's 2027 annual meeting, with 198,553,136 votes in favor and 18,689,301 against.
The appointment of Ernst & Young LLP as the company's independent auditor for the fiscal year ending December 31, 2024, was ratified with 228,845,897 votes for and 174,119 against.
A proposal granting the company's Board of Directors the power to amend the company's bylaws without stockholder approval was not passed. The vote count revealed 112,727,437 in favor and 104,506,389 against, with 134,366 abstentions.
Furthermore, the company's executive compensation plan received approval in a non-binding, advisory vote, with 180,775,070 votes in favor, while 36,417,839 votes were cast against.
10x Genomics, headquartered at 6230 Stoneridge (NYSE:SRI) Mall Road, Pleasanton, California, has its Class A common stock listed on The Nasdaq Stock Market under the trading symbol TXG.
This news is based on a press release statement and reflects the latest corporate governance developments at 10x Genomics. Shareholders' decisions at the Annual Meeting are crucial for the company's future direction and the oversight of its management and financial practices.
In other recent news, Cathie Wood's ARK ETFs have been actively trading in several key companies. The fund's major transactions involve 10X Genomics Inc , where ARK acquired a substantial number of shares across multiple trading days, indicating a bullish stance on the genomics sector. The fund's confidence in 10X Genomics is further corroborated by Jefferies, which recently initiated coverage on the company with a Hold rating.
Meanwhile, ARK has also shown interest in PagerDuty (NYSE:PD) Inc, Intellia Therapeutics (NASDAQ:NTLA) Inc, and several other biotech firms, suggesting a strategic accumulation of stocks in these areas. Conversely, the fund divested significant shares from Zoom Video Communications (NASDAQ:ZM) Inc and Exact Sciences (NASDAQ:EXAS) Corp, which may signal a shift in investment strategy.
Simultaneously, 10X Genomics announced the release of its new Xenium Prime 5K Pan-Tissue and Pathways panel, an advanced assay designed to enhance cellular pathways and biomarker studies. The innovative assay is expected to facilitate rapid analysis of large tissue areas, highlighting 10X Genomics' commitment to innovation and customer-centric product development.
In summary, these recent developments reflect ARK's dynamic investment strategy and the ongoing advancements in the genomics sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.